Advancements in dry eye managment : Episode 15

Overlapping diseases and COVID-19's impact

November 18, 2020

By Brooke Henson, Editor
Tracy Schroeder Swartz, OD, MS, FAAO

Video

EP: 1.Introduction and overview

EP: 2.Consequences and epidemiology of untreated dry eye

EP: 3.Diagnosis and overlooking asymptomatic patients with DED

EP: 4.Standard testing and assessment for DED

EP: 5.General Principles of Treatment of DED

EP: 6.OD and MD communication for optimal care

EP: 7.Review of artificial tears for DED

EP: 8.Corticosteroids and Immunomodulators for the treatment of dry eye

EP: 9.The role of nutritional supplements and antibiotics in DED

EP: 10.How to treat meibomian gland dysfunction

EP: 11.In-office procedures and patient resistance for DED treatments

EP: 12.Treatments for aqueous dry eye

EP: 13.Challenges in the management of DED

EP: 14.Counseling and formulary concerns for DED therapies

EP: 15.Overlapping diseases and COVID-19's impact

EP: 16.Agents in the pipeline for DED

EP: 17.Novel agents in the pipeline for DED

Recent Videos

In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.

Dr Pedram Hamrah

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

Terms & Conditions

Do not sell my Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.